Nourish the kidneys! semaglutide demonstrates strong renal protection and safety in the real world

Compared to placebo, these receptor agonists were found to reduce the risk of kidney failure by 16% and the risk of renal function deterioration by 22%. Overall, the total risk of kidney failure, deterioration of kidney function, and death due to kidney disease decreased by 19%.

The confirmation of previous research results indicates that GLP-1 receptor agonists can reduce the risk of cardiovascular death, non fatal heart attack, and non fatal stroke by 14% compared to placebo. Analysis shows that individuals taking GLP-1 receptor agonists have a 13% reduction in mortality due to any cause.

"This is the first study to show that GLP-1 receptor agonists have obvious benefits for renal failure or end-stage renal disease, indicating that they play a key role in kidney protection and heart protection treatment for patients with type 2 diabetes, overweight or obesity accompanied by cardiovascular disease or CKD and other common diseases," said Professor Sunil Badve, a professor and researcher at the George Global Health Institute and the University of New South Wales in Sydney.

"Our research will have a significant impact on the clinical guidelines for the management of chronic kidney disease and cardiovascular disease in diabetes patients and non diabetes patients," commented Professor Vlado Perkovic, professor and researcher of George Institute, dean of the University of New South Wales in Sydney and senior author of the research.

More work needs to be done now to apply the results of this study to clinical practice and improve access to GLP-1 receptor agonists for those who benefit from it, "Professor Perkovic added.

This study provides strong evidence that the combination therapy of GLP-1RA and SGLT-2i can significantly reduce the risk of renal adverse events, including AKI, ESKD, and all-cause mortality, by 27% compared to SGLT-2i monotherapy. In addition, the benefits of combination therapy were consistent across all subgroups, demonstrating strong renal protection and good safety in real-world environments.